Review



mouse igg2b isotype control  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Bio X Cell mouse igg2b isotype control
    (A,B) 3D killing assays with B16 cells and intra-tumor 4PD1hi or 4PD1− and CD8+ TILs (CD8:CD4=5×104:1×104, suboptimal conditions) FACS-sorted from untreated B16-bearing Foxp3-GFP mice. Mean ± SD percent of killed B16 in co-cultures treated with αPD-1 or αPD-L1 or matched isotype IgGs after 48-hr incubation (n=2–3) (A). Mean ± SD percent of killed B16 in culture with CD8+ TILs and αPD-1- or αPD-L1-pre-treated 4PD1hi or 4PD1− after 48-hr incubation (n=2–3) (B). (C) PD-L1 MFI in 4PD1hi in comparison with 4PD1− and CD8+ T cells from spleen, tumor-draining lymph nodes (DLNs) and tumor in B16-bearing mice (mean ± SEM; n=10). (D) Human NSCLC-derived 4PD1hi, Tregs and 4PD1− were pre-treated with αPD-1 or control isotype <t>IgG</t> and cultured with stimulated autologous (auto) CD8+ TILs at 1:1 ratio for 72 hr. Quantification by Luminex-based bead immunoassay of IFN-γ and IL-2 in CD8+ TIL cultures with αPD-1- or IgG-pre-treated CD4+ T-cell subsets or incubated with αPD-1 or the matched isotype IgG (mean ± SD; n=2 with Tregs and 4PD1hi, n=3 with CD8+ TILs alone; n=4 with IgG-treated 4PD1−; n=6 with αPD-1-treated 4PD1−). Unpaired t test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. See also Figure S5.
    Mouse Igg2b Isotype Control, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 250 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc+controller+block/InVivoMAb+mouse+IgG2b+isotype+control%2C+unknown+specificity/pmc06648657-6-0-7
    Average 94 stars, based on 250 article reviews
    mouse igg2b isotype control - by Bioz Stars, 2026-11
    94/100 stars

    Images

    1) Product Images from "Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity"

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity

    Journal: Cancer cell

    doi: 10.1016/j.ccell.2018.05.009

    (A,B) 3D killing assays with B16 cells and intra-tumor 4PD1hi or 4PD1− and CD8+ TILs (CD8:CD4=5×104:1×104, suboptimal conditions) FACS-sorted from untreated B16-bearing Foxp3-GFP mice. Mean ± SD percent of killed B16 in co-cultures treated with αPD-1 or αPD-L1 or matched isotype IgGs after 48-hr incubation (n=2–3) (A). Mean ± SD percent of killed B16 in culture with CD8+ TILs and αPD-1- or αPD-L1-pre-treated 4PD1hi or 4PD1− after 48-hr incubation (n=2–3) (B). (C) PD-L1 MFI in 4PD1hi in comparison with 4PD1− and CD8+ T cells from spleen, tumor-draining lymph nodes (DLNs) and tumor in B16-bearing mice (mean ± SEM; n=10). (D) Human NSCLC-derived 4PD1hi, Tregs and 4PD1− were pre-treated with αPD-1 or control isotype IgG and cultured with stimulated autologous (auto) CD8+ TILs at 1:1 ratio for 72 hr. Quantification by Luminex-based bead immunoassay of IFN-γ and IL-2 in CD8+ TIL cultures with αPD-1- or IgG-pre-treated CD4+ T-cell subsets or incubated with αPD-1 or the matched isotype IgG (mean ± SD; n=2 with Tregs and 4PD1hi, n=3 with CD8+ TILs alone; n=4 with IgG-treated 4PD1−; n=6 with αPD-1-treated 4PD1−). Unpaired t test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. See also Figure S5.
    Figure Legend Snippet: (A,B) 3D killing assays with B16 cells and intra-tumor 4PD1hi or 4PD1− and CD8+ TILs (CD8:CD4=5×104:1×104, suboptimal conditions) FACS-sorted from untreated B16-bearing Foxp3-GFP mice. Mean ± SD percent of killed B16 in co-cultures treated with αPD-1 or αPD-L1 or matched isotype IgGs after 48-hr incubation (n=2–3) (A). Mean ± SD percent of killed B16 in culture with CD8+ TILs and αPD-1- or αPD-L1-pre-treated 4PD1hi or 4PD1− after 48-hr incubation (n=2–3) (B). (C) PD-L1 MFI in 4PD1hi in comparison with 4PD1− and CD8+ T cells from spleen, tumor-draining lymph nodes (DLNs) and tumor in B16-bearing mice (mean ± SEM; n=10). (D) Human NSCLC-derived 4PD1hi, Tregs and 4PD1− were pre-treated with αPD-1 or control isotype IgG and cultured with stimulated autologous (auto) CD8+ TILs at 1:1 ratio for 72 hr. Quantification by Luminex-based bead immunoassay of IFN-γ and IL-2 in CD8+ TIL cultures with αPD-1- or IgG-pre-treated CD4+ T-cell subsets or incubated with αPD-1 or the matched isotype IgG (mean ± SD; n=2 with Tregs and 4PD1hi, n=3 with CD8+ TILs alone; n=4 with IgG-treated 4PD1−; n=6 with αPD-1-treated 4PD1−). Unpaired t test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. See also Figure S5.

    Techniques Used: Incubation, Comparison, Derivative Assay, Control, Cell Culture, Luminex

    (A–B) Heatmaps with unsupervised hierarchical clustering and single-sample gene set enrichment analysis (ssGSEA) scores of TFH-associated genes in gene expression data sets from functionally validated mouse splenic (A) and donor-derived (B) 4PD1hi, 4PD1− and Tregs. *, Wilcoxon matched-pairs signed-rank test p=0.03125 (mean ± SEM; A, n=3; B, n=5). (C) 4PD1hi (percent of CD4+ T cells, left; proportion of total cells, right) in tumors from B16-bearing Batf KO or wild-type (WT) mice treated with αCTLA-4 or control isotype IgG (100 μg x4) as assessed by FACS (mean ± SEM; WT mice, n=10; Batf KO mice, n=6–7; unpaired t test) or immunofluorescence staining (IF; mean ± SEM; n=3; unpaired t test). (D) CD86 MFI on circulating B220+CD45+ B cells from B16-bearing mice treated with αCTLA-4 or control isotype IgG (100 μg x4) (left; mean ± SEM; n=9–10, unpaired t test), and on circulating CD19+CD45+ B cells before and during ipilimumab treatment (ipi) in metastatic melanoma patients (right; 3 mg/kg, q3wks; n=16; paired t test). (E,F) In vitro suppression assays with 4PD1hi, memory CD4+ T cells (CD44hiPD-1−Foxp3−CD4+ T cells, Tmem) and Tregs from tumors (E) and spleens (F) of αCTLA-4-treated (100 μg x4) B16-bearing Foxp3-GFP mice at the indicated effector:target ratios. 4PD1hi, Tmem and Tregs FACS gating strategy and baseline CD44 expression after sorting is depicted (E top). Data show mean ± SD proliferation (CTVlow) and activation (CD25+CD44+) of target CD8+ and CD4+ T cells from 48- and 72-hr co-cultures respectively (n=3; E, unpaired t test; F, 2-way ANOVA, 4PD1hi and Tregs vs Tmem). ** = p<0.01, **** = p<0.0001. See also Figure S6.
    Figure Legend Snippet: (A–B) Heatmaps with unsupervised hierarchical clustering and single-sample gene set enrichment analysis (ssGSEA) scores of TFH-associated genes in gene expression data sets from functionally validated mouse splenic (A) and donor-derived (B) 4PD1hi, 4PD1− and Tregs. *, Wilcoxon matched-pairs signed-rank test p=0.03125 (mean ± SEM; A, n=3; B, n=5). (C) 4PD1hi (percent of CD4+ T cells, left; proportion of total cells, right) in tumors from B16-bearing Batf KO or wild-type (WT) mice treated with αCTLA-4 or control isotype IgG (100 μg x4) as assessed by FACS (mean ± SEM; WT mice, n=10; Batf KO mice, n=6–7; unpaired t test) or immunofluorescence staining (IF; mean ± SEM; n=3; unpaired t test). (D) CD86 MFI on circulating B220+CD45+ B cells from B16-bearing mice treated with αCTLA-4 or control isotype IgG (100 μg x4) (left; mean ± SEM; n=9–10, unpaired t test), and on circulating CD19+CD45+ B cells before and during ipilimumab treatment (ipi) in metastatic melanoma patients (right; 3 mg/kg, q3wks; n=16; paired t test). (E,F) In vitro suppression assays with 4PD1hi, memory CD4+ T cells (CD44hiPD-1−Foxp3−CD4+ T cells, Tmem) and Tregs from tumors (E) and spleens (F) of αCTLA-4-treated (100 μg x4) B16-bearing Foxp3-GFP mice at the indicated effector:target ratios. 4PD1hi, Tmem and Tregs FACS gating strategy and baseline CD44 expression after sorting is depicted (E top). Data show mean ± SD proliferation (CTVlow) and activation (CD25+CD44+) of target CD8+ and CD4+ T cells from 48- and 72-hr co-cultures respectively (n=3; E, unpaired t test; F, 2-way ANOVA, 4PD1hi and Tregs vs Tmem). ** = p<0.01, **** = p<0.0001. See also Figure S6.

    Techniques Used: Gene Expression, Derivative Assay, Control, Immunofluorescence, Staining, In Vitro, Expressing, Activation Assay

    (A) In vitro suppression assays with 4PD1hi, Tregs and 4PD1− from spleens of sRBC-immunized or control B16-bearing Foxp3-GFP mice at the indicated ratios. Mean ± SD proliferation (CTVlow) and activation (CD25+CD44+) of target CD4+ T cells, and Foxp3 and PD-1 MFI in CD45.1− 4PD1hi, 4PD1− or Tregs from the same co-cultures after 48-hr incubation (n=2–3; 2-way ANOVA, NT-4PD1hi vs sRBC-4PD1hi). (B) In vitro suppression assays with CXCR5+ and CXCR5− 4PD1hi, 4PD1− and Tregs from spleens (SP) and tumors (TM) of naive and B16-bearing (TB) Foxp3-GFP mice immunized with sRBC. Mean ± SD proliferation (CTVlow) of target CD45.1+CD4+ T cells and quantification of IL-2 by Luminex-based bead immunoassay in culture supernatants after 72-hr incubation with effector cells (1:1 ratio; 4×104 cells from SP; 1×104 cells from TM; n=2–4; unpaired t test). (C) In vitro suppression assays with 4PD1hi, CD44hiPD-1−Foxp3−CD4+ Tmem and Foxp3+ Tregs from spleens of sRBC-immunized Foxp3-GFP mice at the indicated effector:target ratios. Mean ± SD proliferation (CTVlow) and activation (CD25+CD44+) of target CD8+ and CD4+ T cells from 48- and 72-hr co-cultures respectively (n=2–3; 2-way ANOVA, 4PD1hi and Tregs vs Tmem). (D) Average ± SEM tumor diameter of B16-bearing Sh2d1a (SAP) KO and WT C57BL/6J mice treated with αCTLA-4 or control isotype IgG (100 μg x4) starting on day 7 after tumor implantation (suboptimal treatment) (n=4–5; 2-way ANOVA with Bonferroni correction). * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. See also Figure S7.
    Figure Legend Snippet: (A) In vitro suppression assays with 4PD1hi, Tregs and 4PD1− from spleens of sRBC-immunized or control B16-bearing Foxp3-GFP mice at the indicated ratios. Mean ± SD proliferation (CTVlow) and activation (CD25+CD44+) of target CD4+ T cells, and Foxp3 and PD-1 MFI in CD45.1− 4PD1hi, 4PD1− or Tregs from the same co-cultures after 48-hr incubation (n=2–3; 2-way ANOVA, NT-4PD1hi vs sRBC-4PD1hi). (B) In vitro suppression assays with CXCR5+ and CXCR5− 4PD1hi, 4PD1− and Tregs from spleens (SP) and tumors (TM) of naive and B16-bearing (TB) Foxp3-GFP mice immunized with sRBC. Mean ± SD proliferation (CTVlow) of target CD45.1+CD4+ T cells and quantification of IL-2 by Luminex-based bead immunoassay in culture supernatants after 72-hr incubation with effector cells (1:1 ratio; 4×104 cells from SP; 1×104 cells from TM; n=2–4; unpaired t test). (C) In vitro suppression assays with 4PD1hi, CD44hiPD-1−Foxp3−CD4+ Tmem and Foxp3+ Tregs from spleens of sRBC-immunized Foxp3-GFP mice at the indicated effector:target ratios. Mean ± SD proliferation (CTVlow) and activation (CD25+CD44+) of target CD8+ and CD4+ T cells from 48- and 72-hr co-cultures respectively (n=2–3; 2-way ANOVA, 4PD1hi and Tregs vs Tmem). (D) Average ± SEM tumor diameter of B16-bearing Sh2d1a (SAP) KO and WT C57BL/6J mice treated with αCTLA-4 or control isotype IgG (100 μg x4) starting on day 7 after tumor implantation (suboptimal treatment) (n=4–5; 2-way ANOVA with Bonferroni correction). * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. See also Figure S7.

    Techniques Used: In Vitro, Control, Activation Assay, Incubation, Luminex, Tumor Implantation

    KEY RESOURCES TABLE
    Figure Legend Snippet: KEY RESOURCES TABLE

    Techniques Used: Purification, Blocking Assay, Control, Virus, Recombinant, Staining, Gene Expression, Knock-Out, Transgenic Assay, Software

    Related Articles

    Control:

    Article Title: Transcriptomic profiling of mouse mammary tumors enables prognostic and predictive biomarker discovery for human breast cancers
    Article Snippet: .. The following antibodies and doses were used: anti-PD1 (250 ug, Bio X Cell, BE0146, RRID:AB_10949053), anti-CTLA4 (125 ug, Bio X Cell, BE0164, RRID:AB_10949609), CD40AG (100 ug, Bio X Cell, BE0016-2, RRID:AB_1107647), IgG2a isotype control (125 ug, Bio X Cell, BE0089, RRID:AB_1107769), and IgG2b isotype control (125 ug, Bio X Cell, BE0086, RRID:AB_1107791). ..

    Article Title: Inhibition of cell surface GRP78 and activated α 2M interaction attenuates kidney fibrosis
    Article Snippet: .. Three separate studies were conducted: (a) treatment with C38 (made in-house) or the isotype control IgG2b (BioXcell, BE0086) antibodies; (b) Fα2M (made in-house) or the isotype control IgG1 (BioXcell, BE0083) antibodies; or (c) P19 or scrambled control peptide (both made in-house). ..

    Article Title: Inhibition of cell surface GRP78 and activated α2M interaction attenuates kidney fibrosis.
    Article Snippet: .. Three separate studies were conducted: (a) treatment with C38 (made in-house) or the isotype control IgG2b (BioXcell, BE0086) antibodies; (b) Fα2M (made in-house) or the isotype control IgG1 (BioXcell, BE0083) antibodies; or (c) P19 or scrambled control peptide (both made in-house). ..

    Article Title: IL-35 produced by dendritic cells via TIM-3-STAT3 signaling contributes to the development of visceral leishmaniasis
    Article Snippet: The following antibodies were used for flow cytometry: PE-anti-mouse EBI3 (IC18341P) and APC-anti-human/mouse IL-12p35 (IC2191A) (both from R&D Systems); eFluor 660-anti-mouse IL-12p35 (50-7352-82), PerCP-anti-mouse/human IL-12p35 (MA5-23622) and Alexa Fluor 594-anti-mouse IgG (A-11020; all from Thermo Fisher Scientific); PE-anti-human EBI3 (360903), FITC-anti-mouse CD40 (124608), FITC-anti-mouse CD86 (105006), FITC-anti-mouse CD80 (104706), FITC-anti-mouse CD11c (117306), PE-anti-mouse CD8α (100708), FITC-anti-mouse CD8α (100706), PE/Cyanine7-anti-mouse CD3 (100220), PerCP/Cyanine5.5-anti-mouse CD4 (100434), Alexa Fluor 647-anti-mouse IDO1 (654003), APC-anti-mouse IL-10 (505010), FITC-anti-mouse IFNγ (505806) and isotype control antibodies such as FITC-rat IgG2a,κ (400505) and FITC-armenian hamster IgG (400905; all from Biolegend, CA, USA). .. Neutralization studies were performed using neutralizing anti-IL-35 (clone V1.4C4.22, MABF848; Sigma-Aldrich) and the corresponding isotype control mouse IgG2b (BE0086; Bio X Cell, NH, USA). .. The TIM-3 blocking antibody (clone RMT3-23, BE0115) ( Chiba et al ., 2012 ) and the isotype control rat IgG2a,κ (BE0089) were obtained from Bio X Cell.

    Article Title: Removal of Interstitial Hyaluronan Facilitates Subcutaneous Administration and Lymphatic Delivery of Anti-CTLA4 and Improves Antitumor Efficacy
    Article Snippet: Subcutaneous administration is an increasingly patientpreferred, alternative route of administration for monoclonal antibodies (mAb).. To overcome the dose-volume restriction with subcutaneous administration and enable the large mAb doses typically required for immunotherapy, recombinant human hyaluronidase PH20 is co-dosed to transiently depolymerize hyaluronan at the injection site.. Despite increasing clinical approvals and clinical trials of combination products with PH20, the potential impact of PH20 in facilitating intravenous-to-subcutaneous dose switching is largely unknown.

    other:

    Article Title: A Developmental Lectin-Glycan Program Enables Early Breast Cancer Dissemination and Metastatic Onset
    Article Snippet: Secondary antibodies used were Alexa Fluor 488 goat anti-mouse (Abcam ab150113; 1:1000) and Alexa Fluor 568 goat anti-rabbit (Abcam ab150080; 1:1000).

    Neutralization:

    Article Title: IL-35 produced by dendritic cells via TIM-3-STAT3 signaling contributes to the development of visceral leishmaniasis
    Article Snippet: The following antibodies were used for flow cytometry: PE-anti-mouse EBI3 (IC18341P) and APC-anti-human/mouse IL-12p35 (IC2191A) (both from R&D Systems); eFluor 660-anti-mouse IL-12p35 (50-7352-82), PerCP-anti-mouse/human IL-12p35 (MA5-23622) and Alexa Fluor 594-anti-mouse IgG (A-11020; all from Thermo Fisher Scientific); PE-anti-human EBI3 (360903), FITC-anti-mouse CD40 (124608), FITC-anti-mouse CD86 (105006), FITC-anti-mouse CD80 (104706), FITC-anti-mouse CD11c (117306), PE-anti-mouse CD8α (100708), FITC-anti-mouse CD8α (100706), PE/Cyanine7-anti-mouse CD3 (100220), PerCP/Cyanine5.5-anti-mouse CD4 (100434), Alexa Fluor 647-anti-mouse IDO1 (654003), APC-anti-mouse IL-10 (505010), FITC-anti-mouse IFNγ (505806) and isotype control antibodies such as FITC-rat IgG2a,κ (400505) and FITC-armenian hamster IgG (400905; all from Biolegend, CA, USA). .. Neutralization studies were performed using neutralizing anti-IL-35 (clone V1.4C4.22, MABF848; Sigma-Aldrich) and the corresponding isotype control mouse IgG2b (BE0086; Bio X Cell, NH, USA). .. The TIM-3 blocking antibody (clone RMT3-23, BE0115) ( Chiba et al ., 2012 ) and the isotype control rat IgG2a,κ (BE0089) were obtained from Bio X Cell.



    Similar Products

    nonlinear mpc controller block  (MathWorks Inc)
    95
    MathWorks Inc nonlinear mpc controller block
    Nonlinear Mpc Controller Block, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc+controller+block/Model+Predictive+Control+Toolbox/10__1007_slash_s10015___025___01040___2-113-8-17
    Average 95 stars, based on 1 article reviews
    nonlinear mpc controller block - by Bioz Stars, 2026-11
    95/100 stars
    		  Buy from Supplier
    mpc controller block  (MathWorks Inc)
    95
    MathWorks Inc mpc controller block
    Mpc Controller Block, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc+controller+block/Model+Predictive+Control+Toolbox/10__1109_slash_tsg__2020__3026361-223-7-6
    Average 95 stars, based on 1 article reviews
    mpc controller block - by Bioz Stars, 2026-11
    95/100 stars
    		  Buy from Supplier
    mpc block of the model predictive control toolbox  (MathWorks Inc)
    90
    MathWorks Inc mpc block of the model predictive control toolbox
    Mpc Block Of The Model Predictive Control Toolbox, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc+controller+block/10__1002_slash_acs__2946-261-18-27
    Average 90 stars, based on 1 article reviews
    mpc block of the model predictive control toolbox - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    mpc controller imulink block of matlab mpc toolbox  (MathWorks Inc)
    90
    MathWorks Inc mpc controller imulink block of matlab mpc toolbox
    Mpc Controller Imulink Block Of Matlab Mpc Toolbox, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc+controller+block/10__1016_slash_j__jprocont__2018__09__004-266-27-27
    Average 90 stars, based on 1 article reviews
    mpc controller imulink block of matlab mpc toolbox - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    block of model predictive control (mpc)  (MathWorks Inc)
    90
    MathWorks Inc block of model predictive control (mpc)
    Block Of Model Predictive Control (Mpc), supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc+controller+block/10__1515_slash_ijame___2018___0007-10-12-12
    Average 90 stars, based on 1 article reviews
    block of model predictive control (mpc) - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    mpc control system block  (Maglev Inc)
    90
    Maglev Inc mpc control system block
    Mpc Control System Block, supplied by Maglev Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc+controller+block/mpc+control+system+block/10__1016_slash_j__jprocont__2013__10__016-165-7-13
    Average 90 stars, based on 1 article reviews
    mpc control system block - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results